neuroendocrine tumors, soft tissue sarcoma
Conditions
Brief summary
Proportion of patients experiencing grade 3 or higher adverse events, Number of patients showing enhancement in the proportion of circulating immune effectors specific for a selected panel of associated antigens for each disease
Detailed description
Overall survival; relapse-free survival, Proportion of patients with positive DHT test will be calculated and the predictive role will be analyzed taking account of the relationship with the primary and the other secondary outcomes, All the immunological objectives will be calculated in terms of proportion and the correlation with efficacy and safety parameters will be explored
Interventions
Sponsors
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients experiencing grade 3 or higher adverse events, Number of patients showing enhancement in the proportion of circulating immune effectors specific for a selected panel of associated antigens for each disease | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival; relapse-free survival, Proportion of patients with positive DHT test will be calculated and the predictive role will be analyzed taking account of the relationship with the primary and the other secondary outcomes, All the immunological objectives will be calculated in terms of proportion and the correlation with efficacy and safety parameters will be explored | — |
Countries
Italy
Outcome results
None listed